Home > Insider Trading > Filing (0001181431-12-053461)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1365216	Sucampo Pharmaceuticals Inc.	SCMP	Pharmaceutical Preparations (2834)	133929237

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1383384	Sachiko Kuno	4520 East-West Highway Suite 300 Bethesda MD 20814		No	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Class A Common Stock	Acquisiton	2012-08-30	26,191,050	$0.00	26,400,802	No	4	X	Indirect	By S&R Technology Holdings, Inc.
Class A Common Stock	Disposition	2012-10-01	38,450	$5.15	26,362,352	No	4	S	Indirect	By S&R Technology Holdings, Inc.

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	X	Indirect	By S&R Technology Holdings, Inc.
No	4	S	Indirect	By S&R Technology Holdings, Inc.

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Class A Common Stock	Class B Common Stock	Disposition	2012-08-30	26,191,050	$0.00	26,191,050	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	X	Indirect

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Class A Common Stock	52,037	Direct
Class A Common Stock	148,530	Indirect	By Husband

Footnotes

Shares acquired upon conversion of shares of Class B Common Stock on a one-for-one basis.
S&R Technology Holdings, LLC is wholly owned by Dr. Kuno and her husband. Dr. Kuno disclaims beneficial ownership of the reported securities except to the extent of her pecuniary interest therein.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.02 to $5.24, inclusive. The reporting person undertakes to provide to Sucampo Pharmaceuticals, Inc., any security holder of Sucampo Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Dr. Kuno disclaims beneficial ownership of the reported securities.
Each share of Class B Common Stock is convertible at any time into one share of Class A Common Stock without further consideration.
Taking into account all applicable stock splits, S&R Technology Holdings, LLC obtained (i) 2,465,000 shares of Class B Common Stock for $290,000, (ii) 11,722,350 shares of Class B Common Stock for $2,413,425, and (iii) 12,003,700 shares of Class B Common Stock for $1,999,958.